Skip to main content
SpringerLink
Log in

The immunological status of breast cancer patients during treatment with a new antiestrogen, toremifene

  • Original articles
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Summary

The immune status of breast cancer patients was followed during antiestrogen treatment for at least 1 year or until progression of the disease. Twelve postmenopausal women with advanced estrogen-receptor-positive breast cancer were treated with a novel antiestrogen, toremifene. Immune functions were determined before the start of the treatment and at 3, 6, and 12 months. For NK cell cytotoxicity testing there were 74 healthy controls and for T cell subset measurements 28 healthy controls. No statistically significant changes in the T cell subsets or NK cell cytotoxicity were observed during treatment. However, throughout toremifene treatment patients had fewer CD4 cells (T helper lymphocytes) than did the controls. Cancer patients had higher pretreatment B cell values than the controls,P = 0.01, but during the first months of toremifene treatment B cell values decreased and remained within the normal range thereafter. A positive effect on mitogen-stimulation tests with phytohemagglutinin (PHA) and concanavalin A (ConA) was observed during the first months of treatment (P = 0.01 for PHA and 0.03 for log [ConA] and a stabilization at the higher level thereafter. These results indicate that toremifene has a stimulatory effect on cell-mediated immunity in breast cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Adler A, Stein JA, Ben-Efraim S (1980) Immunocompetence, immunosuppression, and human breast cancer. III. Prognostic significance of initial level of immunocompetence in early and advanced disease. Cancer 45: 2074

    Google Scholar 

  2. Berry J, Green BJ, Matheson DS (1987) Modulation of natural killer cell activity by tamoxifen in stage I postmenopausal breast cancer. Eur J Cancer Clin Oncol 23: 517

    Google Scholar 

  3. Cohen JHM, Danel L, Cordier G, Saez S, Revillard JP (1983) Sex steroid receptors in peripheral T cells: absence of androgen receptors and restriction of estrogen receptors to OKT8 positive cells. J Immunol 131: 2767

    Google Scholar 

  4. Dillman RO, Koziol JA, Zavanelli MI et al. (1984) Immunoincompetence in cancer patients. Cancer 53: 1484

    Google Scholar 

  5. Eskola J, Soppi E, Viljanen M, et al. (1975) A new micromethod for lymphocyte stimulation using whole blood. Immunol Commun 4: 297

    Google Scholar 

  6. Giorgi JV (1986) Lymphocyte subset measurements: significance in clinical medicine. In: Rose NR, Friedman H, Fahey JL (eds) Manual of Clinical an Laboratory Immunology. 3rd ed. Am Soc Microbiol, Washington, DC, p 236

    Google Scholar 

  7. Grossman CJ (1984) Regulation of the immune system by sex steroids. Endocrinol Rev 5: 435

    Google Scholar 

  8. Joensuu, H, Toivanen A, Nordman E (1986) Effect of tamoxifen on immune functions. Cancer Treat Rep 70: 381

    Google Scholar 

  9. Kallio S, Kangas L, Blanco G et al. (1986) A new triphenylethylene compound, FC-1157 A. I. Hormonal effects. Cancer Chemother Pharmacol 17: 103

    Google Scholar 

  10. Kangas L, Nieminen A-L, Blanco, G et al. (1986) A new triphenylethylene compound, FC-1157 A. II. Antitumour effects. Cancer Chemother Pharmacol 17: 109

    Google Scholar 

  11. Mandeville R, Lamoureux G, Legault-Poisson S, Poisson R (1982) Biological markers and breast cancer. A multiparametric study. II. Depressed immune competence. Cancer 50: 1280

    Google Scholar 

  12. Mandeville R, Ghali SS, Chausseau JP (1984) In vitro stimulation of human NK activity by an estrogen antagonist (Tamoxifen). Eur J Cancer Clin Oncol 20: 983

    Google Scholar 

  13. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207

    Google Scholar 

  14. Paavonen T, Anderson LC (1985) The oestrogen antagonists, tamoxifen and FC-1157 a, display oestrogen like effects on human lymphocyte functions in vitro. Clin Exp Immunol 61: 467

    Google Scholar 

  15. Paavonen T, Andersson LC, Adlercreuz H (1981) Sex hormone regulation of in vitro immune response. J Exp Med 154: 1935

    Google Scholar 

  16. Paterson AG, Webster DJT (1982) The predictive value of T-lymphocyte counts in advanced breast-cancer patients treated with tamoxifen. Br J Cancer 45: 637

    Google Scholar 

  17. Rotstein S, Blomgren H, Petrini B, Wasserman J, Nilsson B, Baral E (1985) Blood lymphocyte counts with subset analysis in operable breast cancer. Relation to the extent of tumor disease and prognosis. Cancer 56: 1413

    Google Scholar 

  18. Rotstein S, Blomgren H, Petrini B, Wasserman J, Baral E (1985) Long term effects on the immune system following local radiation therapy for breast cancer. I. Cellular composition of the peripheral blood lymphocyte population. Int J Radiat Oncology Biol Phys 11: 921

    Google Scholar 

  19. Rotstein S, Blomgren H, Petrini B, Wasserman J, Baral E (1986) Long-term effects on the immune system following local radiation therapy for breast cancer: 4. Proliferative responses and induction of suppressor activity of the blood lymphocyte population. Radiother Oncol 6: 223

    Google Scholar 

  20. Salo M (1987) Surgery and the immune response. In: Paubert-Braquet M (ed) Lipid mediators in the immunology of shock. Plenum, New York, p 289

    Google Scholar 

  21. Scambia G, Panici PB, Maccio A et al. (1988) Effects of antiestrogen and progestin on immune functions in breast cancer patients. Cancer 61: 2214

    Google Scholar 

  22. Sheard CR, Reilly F, Tee DEH et al. (1986) The effect of adjuvant cyclophosphamide or tamoxifen on the numbers of lymphocytes bearing T cell or NK cell markers. Br J Cancer 54: 705

    Google Scholar 

  23. Toivanen A, Nordman E (1981) Long-term effect of postoperative irradiation on the immune fuctions in patients with mammary carcinoma. Acta Radiol Oncol 20: 119

    Google Scholar 

  24. Valavaara R, Pyrhönen S, Heikkinen M et al. (1988) Toremifene, a new antiestrogenic compound for treatment of advanced breast cancer. Phase II study. Eur J Cancer Clin Oncol 24: 785

    Google Scholar 

  25. Webster DJT, Richardson G, Baum M, Priestman T, Hughes LE (1979) Effect of treatment on the immunological status of women with advanced breast cancer. Br J Cancer 39: 676

    Google Scholar 

  26. West WH, Cannon GB, Kay HD, Bonnard GD, Herberman RB (1977) Natural cytotoxic reactivity of human lymphocytes against a myeloid cell line: characterization of effector cells. J Immunol 118: 355

    Google Scholar 

  27. Wärri A, Kangas L (1990) Effect of toremifene on the activity of NK-cells in NZB/NZW mice. J Steroid Biochem (in press)

  28. Zaccheo T, Ornati G, di Salle E (1986) Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the rat. 14th International Cancer Congress, Budapest. Abstr 2996

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiotherapy, University Central Hospital of Turku, SF-20 520, Turku, Finland

    Ritva Valavaara

  2. Department of Biostatistics, University of Turku, 20 520, Turku, Finland

    Juhani Tuominen

  3. Department of Medicine, University of Turku, 20 520, Turku, Finland

    Auli Toivanen

  4. Department of Medical Microbiology, University of Turku, 20 520, Turku, Finland

    Auli Toivanen

Authors
  1. Ritva Valavaara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Juhani Tuominen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Auli Toivanen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Valavaara, R., Tuominen, J. & Toivanen, A. The immunological status of breast cancer patients during treatment with a new antiestrogen, toremifene. Cancer Immunol Immunother 31, 381–386 (1990). https://doi.org/10.1007/BF01741410

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01741410

Keywords

Search

Navigation